Peptide Dose Simulator
Visualize how a peptide accumulates and clears from plasma over a dosing schedule. Enter the pharmacokinetic parameters and see the concentration curve in real time. Works for BPC-157, TB-500, CJC-1295, Ipamorelin, semaglutide, and any compound with a known half-life.
How to use: Enter a compound's half-life (find it on the compound wiki), time to peak, dose frequency, and duration. The chart shows relative plasma concentration — 1.0 = peak concentration from a single dose. Overlay multiple compounds to compare accumulation patterns.
Enter at least one compound with a name and half-life to see the curve
Bridge from simulation to tracking
Know the curve, then track the real protocol.
Use the simulator to pressure-test timing, then use Staqk to log actual doses, keep reminders aligned with the plan, and compare what happened against what you expected.
How to read the chart
The Y axis shows concentration relative to the peak of a single dose (1.0 = 100% of single-dose peak). With repeated dosing, concentrations accumulate until reaching steady state — typically after 4–5 half-lives. The accumulation factor shows how much higher steady-state levels are compared to a single dose.
What is half-life?
Half-life is the time for plasma concentration to fall by 50%. After one half-life, 50% remains. After two half-lives, 25% remains. After five half-lives, only ~3% remains — this is considered clinical clearance.
Limitations
This is a simplified pharmacokinetic model (linear absorption + first-order elimination). Real plasma curves vary with individual metabolism, injection site, volume, and tissue binding. Use this as an educational tool only, not for clinical decision-making.
Common peptide half-lives
Use these values as starting points when building your dosing simulation. BPC-157: ~4 hours (subcutaneous). TB-500: ~3–4 days. CJC-1295 without DAC: ~30 minutes (requires frequent dosing or GHRP combination). CJC-1295 with DAC: ~6–8 days (weekly dosing). Ipamorelin: ~2 hours. Semaglutide: ~7 days (true weekly dosing). Tirzepatide: ~5 days. Retatrutide: ~6 days. NAD+: ~1–2 hours (subcutaneous). GHK-Cu: ~1 hour. For the most accurate compound half-life data, check the compound's entry in the compound wiki.
BPC-157 dosage simulator
BPC-157 has a short half-life of approximately 4 hours subcutaneously, which means once-daily dosing produces a single daily peak with minimal accumulation. Twice-daily dosing (every 12 hours) keeps plasma levels more consistent throughout the day — preferred for acute injury protocols. Enter half-life: 4, Tmax: 1, and your target frequency to visualize how BPC-157 concentrations build over a protocol. TB-500's much longer half-life (~3–4 days) means once or twice weekly dosing is sufficient to maintain steady-state levels.